Did Rebel Wilson confirm using Ozempic?

Yes. Wilson confirmed in a 2023 People magazine interview that she used Ozempic as part of her weight-loss approach during her 2020 "Year of Health." She initially attributed her results to diet and exercise alone before disclosing the medication.

Why did Rebel Wilson regain weight after stopping Ozempic?

Wilson's weight regain after discontinuation is consistent with established clinical data. The STEP 1 extension study showed participants regained approximately two-thirds of lost weight within one year of stopping semaglutide. This occurs because the biological mechanisms driving appetite and energy storage reassert themselves once the drug is removed (Wilding et al., 2022).

Is Ozempic the same as Wegovy?

Both contain semaglutide, but they differ in approved indication and dosing. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. Many physicians prescribe Ozempic off-label for weight loss, though patients receive a lower maximum dose than the Wegovy regimen used in the STEP trials (FDA label).

What are the common side effects of semaglutide?

The most frequently reported side effects are gastrointestinal: nausea (affecting up to 44% of patients at the 2.4 mg dose), diarrhea, vomiting, and constipation. These are typically most pronounced during dose escalation and tend to decrease over time. Less common but serious risks include pancreatitis, gallbladder disease, and a boxed warning regarding medullary thyroid carcinoma risk based on animal studies (Wilding et al., NEJM 2021).

Should people stay on GLP-1 medications indefinitely?

Current evidence suggests that for many patients, long-term or indefinite use produces the best outcomes. The Endocrine Society and other professional bodies have moved toward treating obesity as a chronic condition requiring ongoing management, similar to hypertension or diabetes. Discontinuation without a structured maintenance plan frequently leads to significant weight regain (Endocrine Society guidelines).

Rebel Wilson and GLP-1: The Documented Public Record

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Rebel Wilson and GLP-1: The Documented Public Record Image: HealthRX.com clinical image

The Public Timeline

Rebel Wilson announced 2020 as her "Year of Health," sharing progress on Instagram throughout that year. Early interviews emphasized a high-protein diet, daily walking, and work with a personal trainer. She told People magazine that she reached her goal weight of 75 kg (165 lb) by November 2020, down from an estimated 105+ kg.

The initial public narrative centered entirely on lifestyle changes. Wilson discussed emotional eating patterns and credited the Mayr Method, a European wellness protocol focused on gut health, with helping shift her relationship to food.

It was not until later interviews that Wilson confirmed she had also used Ozempic (semaglutide 0.5 mg / 1 mg) during this period. In a 2023 interview, she acknowledged to People that she "felt like a fraud" for not disclosing the medication earlier, stating she had used it alongside her lifestyle interventions.

Wilson has since discussed publicly that she experienced weight regain after discontinuing the drug. She described the rebound as frustrating and noted the difficulty of maintaining results without ongoing pharmaceutical support.

What Ozempic Actually Does

Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, which is released from the gut after eating.

The drug works through several parallel mechanisms. It slows gastric emptying, so food stays in the stomach longer. It acts on hypothalamic appetite centers to reduce hunger signaling. And it enhances glucose-dependent insulin secretion from pancreatic beta cells. The net effect: patients eat less, feel full sooner, and maintain more stable blood glucose levels (Wilding et al., NEJM 2021).

At the FDA-approved weight-management dose of 2.4 mg weekly (Wegovy), the STEP 1 trial demonstrated a mean weight loss of 14.9% of body weight over 68 weeks, compared with 2.4% for placebo. Wilson's confirmed use was Ozempic, which is dosed at up to 2 mg weekly for glycemic control and is not FDA-approved specifically for weight loss, though physicians frequently prescribe it off-label for that purpose (FDA Ozempic label).

The Rebound Problem: What the Data Shows

Wilson's publicly discussed weight regain is not an outlier. It is the expected clinical outcome when semaglutide is stopped.

The STEP 1 trial extension study, published in Diabetes, Obesity and Metabolism in 2022, tracked participants for one year after they stopped semaglutide. The findings were stark: participants regained two-thirds of the weight they had lost within 12 months of discontinuation. Cardiometabolic improvements in blood pressure, lipid levels, and HbA1c also reversed (Wilding et al., Diabetes Obes Metab 2022).

This pattern is consistent with what obesity medicine specialists have argued for decades: obesity is a chronic disease requiring chronic treatment. The biological drivers of weight regain, including reduced resting metabolic rate, increased ghrelin signaling, and altered leptin sensitivity, persist after weight loss regardless of the method used (Sumithran et al., NEJM 2011).

The HealthRX.com Medical Team Take

Wilson's timeline illustrates a pattern the HealthRX.com Medical Team sees repeatedly in public GLP-1 narratives. The sequence goes: dramatic weight loss attributed to willpower, delayed pharmaceutical disclosure, then public frustration when discontinuation leads to regain.

From a clinical standpoint, there is nothing surprising about any stage of this sequence. Semaglutide is effective while patients take it. Weight returns when they stop. The STEP 1 extension data confirms this is not a failure of individual discipline but a pharmacological reality.

The HealthRX.com Medical Team notes several points worth highlighting:

Ozempic vs. Wegovy dosing matters. Wilson confirmed Ozempic use specifically. The maximum Ozempic dose (2 mg) is lower than the Wegovy weight-management dose (2.4 mg). Patients using Ozempic off-label for weight loss may see somewhat less effect than the headline STEP trial numbers, which used the higher Wegovy dose.

Lifestyle changes were real, not irrelevant. Wilson's dietary and exercise modifications were genuine interventions. Clinical data supports that GLP-1 agonists produce better outcomes when combined with structured lifestyle changes (Wadden et al., JAMA 2021). The medication and the behavior changes were likely both contributing.

The "fraud" framing is clinically counterproductive. Wilson's statement that she felt like a fraud for using medication reflects a broader cultural stigma around pharmacotherapy for obesity. The American Medical Association recognized obesity as a disease in 2013. Treating a disease with medication is standard care, not deception.

Discontinuation planning is often absent. Many patients start GLP-1 therapy without a clear plan for what happens when they stop, or whether they should stop at all. Current Endocrine Society guidelines recommend considering long-term or indefinite use for patients who respond well, similar to how statins or antihypertensives are prescribed.

At a glance

Status: Rebel Wilson confirmed Ozempic use publicly in 2023
Drug: Ozempic (semaglutide), a GLP-1 receptor agonist
Timeline: Weight loss during 2020 "Year of Health," medication disclosure in 2023, public discussion of weight regain post-discontinuation
Clinical relevance: Her experience mirrors STEP 1 extension data showing ~67% weight regain within one year of stopping semaglutide
Key takeaway: GLP-1 medications treat obesity effectively while active; discontinuation typically leads to significant rebound, as both Wilson's experience and clinical trial data confirm

Frequently asked questions

›

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403-1413. https://jamanetwork.com/journals/jama/fullarticle/2777886
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. https://www.nejm.org/doi/full/10.1056/NEJMoa1105816
FDA. Ozempic (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. https://www.endocrine.org/clinical-practice-guidelines/pharmacological-management-of-obesity